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use of aspirin, UGIB continues to be a problem for those 
with risk factors and especially in patients with a history 
of peptic ulcers, in which UGIB tends to occur early after 
aspirin therapy.
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INTRODUCTION
Anti-platelet therapy with low-dose aspirin (75-325 mg) 
reduces the risk of  vascular events in patients with 
established coronary artery disease (CAD)[1-3]. However, the 
use of  aspirin, even at a low dose for secondary prevention 
of  cardiovascular events, is associated with a small but 
significant increase in the risk of  upper gastrointestinal 
bleeding (UGIB). In addition, previous studies have also 
reported several risk factors, such as the use of  non-
steroidal anti-inflammatory drugs (NSAIDs) and old 
age, implicated in the development of  UGIB in patients 
taking aspirin[4-8]. However, the incidence of  aspirin-
related UGIB in patients with CAD for the secondary 
prevention of  cardiovascular events and the time frame 
of  UGIB occurrence are uncertain. In addition, effects 
of  several emerging therapies, such as the use of  dual 
antiplatelet agents, nitrate or ulcer-protecting drugs for 
the development of  UGIB, have not been systematically 
evaluated.
In a cohort of  patients with established CAD recruited 
into a Cardiac Rehabilitation Programme, we prospectively 
monitored the time of  occurrence of  UGIB in patients 
taking low-dose aspirin for the secondary prevention of  
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Abstract
AIM: The use o f l ow-dose asp i r i n to p reven t 
cardiovascular disease events is well established. However, 
the incidence and predictors of upper gastrointestinal 
bleeding (UGIB) with its use are unknown. We studied 
prospectively the incidence and outcome of peptic 
ulceration in low-dose aspirin users.  
METHODS: A total of 991 patients with coronary artery 
disease (CAD) on low-dose aspirin were prospectively 
followed-up for two years for the occurrence and clinical 
features of first hospitalized episode of UGIB.  
RESULTS: UGIB had a bimodal presentation with 45% 
occurring within four months of aspirin initiation and had 
an overall prevalence of 1.5% per year. There was no 
UGIB-related death. Hypertension (OR = 4.6, 95%CI 1.5 
- 14.7, P = 0.009), history of peptic ulceration (OR = 3.1, 
95%CI 1.1 - 9.0, P  = 0.039), tertiary education (OR = 
3.08, 95%CI 1.1 - 9.0, P = 0.039) and higher lean body 
mass (P = 0.016) were independent factors associated 
with UGIB. Use of nitrate did not reduce UGIB.
CONCLUSION: The incidence of UGIB in patients 
with CAD on long-term low-dose aspirin is low, but is 
accompanied with significant morbidity. With prolonged 
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cardiovascular events over two years. We also sought to 




In this prospective study, we recruited all patients with 
established ischemic heart disease (myocardial infarction, 
angina pectoris, angiographic-proven coronary artery 
disease) referred to a Cardiac Rehabilitation Programme 
in Tung Wah Hospital (an University-affiliated hospital) 
between September 1997 and April 2002. All the patients 
were started on low-dose aspirin (75-300 mg) according to 
referring physicians’ discretion. Apart from collecting data 
on demographics, other parameters related to cardiac reha-
bilitation like education level, functional class, left ventricu-
lar function, exercise capacity, body mass index, body fat 
content, body lean mass content, medications used were 
also recorded. A database was specially designed to collect 
the required information prospectively. Patients were fol-
lowed-up once every 3-4 mo and the occurrence of  UGIB 
was noted. Detailed information about each UGIB event 
was obtained from interpretation and review of  hospital 
records.
Upper gastrointestinal bleeding 
The occurrence of  UGIB was defined as the clinical pre-
sentation of  hematemesis or passage of  melena or unex-
plained drop in hemoglobin of  ≥ 20 g/L. Upper gastro-
intestinal endoscopy with therapeutic intervention(s) to 
obtain haemostasis (using epinephrine injection or heater 
probe application, when needed) was performed in all 
these patients presented with UGIB. Helicobacter pylori (H 
pylori) status was determined using a 24-h rapid urease test 
on antral biopsy specimens and histological detection of  
Helicobacter-like organisms using the haematoxylin and  eo-
sin stain, and Giemsa stain on biopsies taken from the gas-
tric antrum and/or body. The rapid urease test at 24 h has 
been validated in our hospital with a sensitivity and speci-
ficity of  99% and 100%, respectively[9]. In addition, the use 
of  histological examination of  these biopsy specimens, the 
H pylori status was correctly evaluated even in patients with 
active UGIB, with the understanding that rapid urease test 
would be rendered inaccurate at those situations.
Statistical analysis
Univariate analyses were performed, using Student’s t 
test and Mann-Whitney U test for continuous variables 
and Chi-square test or Fisher’s exact test for categorical 
variables to assess the risk factors associated with UGIB. 
A multiple logistic regression model was designed to 
determine the factors (age, gender, educational level, 
occupation, hypertension, diabetes mellitus, renal 
impairment, history of  peptic ulcer diseases, lean body 
mass, body fat, obesity, New York Heart Association 
(NYHA) functional class, left ventricular function, use of  
dual anti-platelet agents/NSAID/ulcer protective drug) 
associated with UGIB. To find the best model, a backward 
elimination stepwise procedure was carried out such 
that the factor would be eliminated from the analysis if  
the corresponding P value was greater than 0.15. A two-
tailed P value of  0.05 or less was considered statistically 
significant. 
RESULTS
Characteristics of patients and incidence of upper 
gastrointestinal bleeding (Table 1)
Between September 1997 and April 2002, a total of  991 
patients with established ischemic heart disease were 
enrolled into the study and followed-up prospectively for 
two years. Of  these, 716 (72.3%) were male (mean age, 
64.8 ± 11 years); 552 (55.7%) had history of  myocardial 
infarction (MI); 541 (54.8%) were hypertensive; 352 (35.5%) 
had diabetic mellitus; and 546 (54.7%) patients were 
smokers. Nitrate use was found in 561 (57.1%) patients. 
One hundred and twelve patients (11.3%) had received 
tertiary education. Twenty-nine patients developed UGIB 
over a follow-up period of  two years, giving the incidence 
of  1.5% per year.  For those who had a bleeding event, 
72% did not have new-onset ulcer pain; 52% required 
blood transfusion (mean, 3.3 units; range, 1-8 units); 62% 
with a drop in hemoglobin of  greater than 3 g/dL; 24% 
of  these patients required more than one therapeutic 
upper gastrointestinal endoscopies for haemostasis. Peptic 
ulceration was the main cause of  UGIB in our series 
(gastric ulcer, 38%; duodenum ulcer, 52%); aspirin-related 
hemorrhagic gastritis did not occur in our cohort. H pylori 
positivity status was present in 50% of  patients presented 
with UGIB.
Of  those who had UGIB, 21% of  all the events 
occurred in the first month and 45% occurred in the first 
4 mo after initiation of  low-dose aspirin (early bleeders) 
(Figure 1). The ‘late bleeders’ (55%) developed UGIB at 
a mean of  20.8 ± 5.3 mo after initiation of  therapy, with 
88% (14/16) of  them bled at least once after one year 
of  aspirin therapy. In addition, about a third of  those 
Table 1 Baseline characteristics of 991 patients with coronary 
artery disease started on low-dose aspirin (mean ± SD, n , %)
                                         No UGIB            UGIB               P  values
                                        (n  = 962)   (n  = 29)
Age (mean  ± SD)   64 ± 11   67 ± 11 0.663
Sex (M/F) 693/268 23/6 0.683
Hypertension (%) 519 (54) 22 (76) 0.008
Diabetes mellitus (%) 342 (35.5) 10 (34.5) 0.906
Renal impairment 
(Cr > 200 umol/L) (%)
  42 (4.4)   5 (17.2) 0.001
Serum creatinine 120 ± 93 158 ± 103 0.002
History of MI (%) 536 (56) 16 (55) 0.095
History of PU (%)   74 (7.7)   9 (31.0) 0.006
LVEF < 40% (%) 388 (40.3) 11 (37.9) 0.034
NYHA (III-IV) (%)   82 (8.5)   6 (20.7) 0.048
% Body fat   34 ± 7   30 ± 7 0.036
% Lean body mass   66 ± 8   70 ± 7 0.049
Education level 
(tertiary) (%)
107 (11.1)   5 (17.2) 0.05
Nitrate use (%) 540 (56.1) 21 (72.4) 0.09
Cr: creatinine; MI: myocardial infarction; PU: peptic ulcer; LVEF: left 
ventricular ejection fraction; NYHA: New York Heart Association functional 
class.
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who presented with UGIB (9/29) had a history of  peptic 
ulcer/GIB/gastrectomy, in which 56% (5/9) of  them 
were early bleeders. This indicates a 1:8 chance of  having 
UGIB in patients with history of  peptic ulceration while 
started on low-dose aspirin, which have a tendency to 
have early bleeding event; 97% of  patients with UGIB 
required hospitalization. Death or myocardial infarction 
did not occur during the UGIB episodes and no patient 
required surgery for treatment of  the UGIB. Nitrate use 
was recorded in 62% of  the bleeders; 21% of  those who 
had an UGIB were on ulcer-protecting drugs during 
presentation, but only 10% of  them reported concurrent 
use of  NSAID.
Predictors of UGIB
Univar iate analyses showed that the presence of  
hypertension (OR = 3.1, 95%CI 1.3 - 7.7, P = 0.008), 
renal impairment (OR = 4.8, 95%CI 1.7 - 13.1, P = 0.001), 
history of  peptic ulcer (OR = 4.6, 95%CI 2.0 - 10.7, P = 
0.002), patients with impaired left ventricle function (EF 
< 40%) (P = 0.034) or NYHA functional class III-IV (OR 
= 3.0, 95%CI 1.2 - 7.6, P = 0.048), patients with high lean 
body mass (70% ± 7% vs 66% ± 8%, P = 0.049) or low 
body fat content (30% ± 7% vs 34% ± 7%, P = 0.036) and 
patients with tertiary education (OR = 3.1, 95%CI 1.1 - 9.0, 
P = 0.05) were predictors of  the development of  UGIB. 
Use of  anti-ulcer therapy (in small number of  patients) was 
not associated in prevention of  UGIB. The use of  nitrate 
did not reduce the risk of  UGIB (P = 0.09). However, 
multivariate analyses using a logistic regression model 
demonstrated that only patients with hypertension (OR = 
4.63, 95%CI 1.5 - 14.7, P = 0.009), history of  peptic ulcer 
(OR = 3.1, 95%CI 1.1 - 9.0, P = 0.039), tertiary education 
(OR = 3.1, 95%CI 1.1 - 9.0, P = 0.039) or with high lean 
body mass (707% ± 7% vs 667% ± 8%, P = 0.0157) had a 
higher probability of  UGIB while taking low-dose aspirin 
for secondary prevention of  cardiovascular events (Table 2).
DISCUSSION
To the best of  our knowledge, this is the first prospec-
tive study for the first UGIB in patients started with low-
dose aspirin for secondary prevention of  cardiovascular 
events. UGIB occurred at a rate of  1.5% per year, and 
was due to peptic ulceration that required hospitalization 
and blood transfusion. Twenty-four percent of  those with 
UGIB required more than one therapeutic endoscopy to 
secure haemostasis. On the other hand, new-onset ulcer 
syndrome was not present in majority of  those patients 
that developed an UGIB. These data also showed that 
when patients started with low-dose aspirin and bled sub-
sequently, 21% of  them had the event in the first month 
of  treatment, 45% of  all bleeding events occurred in the 
first 4 mo of  starting low-dose aspirin; whereas most of  
the other bleeding events took place after at least one year 
of  therapy. This observation implies that not only the risk 
of  UGIB associated with low-dose aspirin use does not 
decrease with time, rather, there exists a bimodal presenta-
tion of  the event in our series with one peak occurring in 
the early phase of  starting treatment and the second oc-
curred beyond the first year. This is in contrary to previous 
studies, in which the rate of  UGIB occurred in a constant 
fashion throughout the entire period of  study[4,8]. There 
are several possible explanations for the difference. Unlike 
other studies, we prospectively recorded first episode of  
UGIB after aspirin initiation instead of  recruiting those 
presenting with the event[5]. In addition, others reported 
the use of  a higher-dose of  aspirin for the prevention of  
cardiovascular events[6]. Furthermore, some animal studies 
reported the possibility of  adaptation of  the gastric muco-
sa to aspirin therapy with time, and this might explain why 
patients begin to have less bleeding after receiving several 
mo of  aspirin therapy[14].
We demonstrated the predictors of  UGIB events for 
patients taking low-dose aspirin. Better-educated people 
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Figure 1 Bimodal presentation of 
upper gastrointestinal bleeding events 
in a two-year follow-up period.
Table 2 Multivariate analysis of predictors of upper 
gastrointestinal bleeding in patients with coronary artery disease 
on low-dose aspirin (mean ± SD)
                                                        95%CI      Odds ratio   P  values
Education level (tertiary) 1.05 - 8.98 3.08 0.039
Hypertension 1.46 - 14.74 4.63 0.009
History of peptic ulcer 1.05 - 9.00 3.08 0.039
% Lean body mass (body fat content) 0.0157
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were more likely to experience UGIB (OR = 3.1, the odds 
of  UGIB was about 3 times more among people who 
received tertiary education than those who received sec-
ondary education or less). One explanation is that better 
educated people might be more compliant to prescribed 
medications, and they generally have much higher pres-
sure/stress at work, and hence have a higher incidence of  
UGIB[10-11]. Consistent to previous reports, patients with a 
past history of  peptic ulcer problems or UGIB were still 
at high risk of  developing UGIB despite the use of  low-
dose aspirin[4].  Furthermore, we showed that most of  
them bled early on initiation of  aspirin and thus deserve 
treatment for ulcer prophylaxis. In our study, patients with 
hypertension had the highest odds ratio for developing 
UGIB, concur with the traditional association between hy-
pertension and the development of  peptic ulcer[15]. Anoth-
er interesting finding was that patients with a higher lean 
body mass had a higher probability for having an UGIB. A 
recent report suggested that obese patients are more prone 
to the development of  aspirin resistance[12], so whether 
non-obese patients with slender-build (and hence a higher 
lean body mass content) are more susceptible to aspirin ef-
fect, including its toxicity on the stomach, will need further 
evaluation. Unlike a previous report[4], the use of  nitrate 
was not linked to a reduction of  UGIB in our study (P = 
0.09). This may be due to a purely statistical problem as a 
large majority (57.1%) of  the CAD patients in our cohort 
were on nitrate, which might mask the protective effect, if  
any of  the latter; alternatively, other confounding factors, 
such as hypertension, leaner subjects in our series, might 
negate the effect of  nitrate. The presence of  renal impair-
ment or heart failure/left ventricular dysfunction was be-
lieved to be predictors of  UGIB as reported in our series 
using an univariate analysis, but these factors dropped out 
after multivariate adjustment. This might be due to the 
small number of  events recorded in the present cohort. 
Our patients were younger (mean, 65 years; range, 35-87 
years) compared to those in the previous study. With this 
age range, age appears not to be a predictive factor for 
UGIB.
The incidence of  UGIB event in patients with CAD 
started on low-dose aspirin was low, and if  occurred, was 
associated with good clinical outcome though most pa-
tients required hospitalisation. Nevertheless, with better 
understanding of  the pathogenesis of  the former and, 
in particular, its relation to H pylori status, our group has 
reported a possible method for the prevention of  recur-
rence of  peptic ulcer complication from long-term low-
dose aspirin use[12].  On the other hand, our study showed 
that certain high-risk group of  patients, especially those 
with history of  peptic ulceration who tend to have early 
UGIB, should be target for primary prevention of  peptic 
ulceration development and continued surveillance needed 
as well for these patients while on low-dose aspirin.
The small number of  patients in our cohort that were 
on regular NSAID (1.1%) might not be able to show its 
deleterious effect on patients taking low-dose aspirin. 
Likewise, there was insufficient number of  patients tak-
ing ulcer-protecting agents 21% to show a statistically 
significant benefit for patients taking these medications for 
ulcer prevention. However, the low usage of  NSAID and 
ulcer-protecting drugs allowed us to determine the natural 
history of  UGIB secondary to low-dose aspirin in this 
patient cohort, in which future therapeutic strategy can 
be planned. Finally, we failed to obtain the H pylori status 
for all patients, Regardless of  whether they had or had not 
had an event, from which the value of  that might be much 
more elicited. In addition, serological assay for H pylori 
infection was not universally available at time of  our study. 
Nevertheless, local study reported that 55% of  the popu-
lation was infected with H pylori though symptoms and 
clinical disease developed in only a minority of  infected 
individuals during their lifetime[13].  
In summary, the incidence of  UGIB in patients with 
CAD on low-dose aspirin remains low at 1.5% per year. 
Patients with hypertension, history of  peptic ulcer prob-
lem, low body fat content (high lean body mass) and 
those that had received tertiary education were at risk of  
having an UGIB event. There exists bimodal presentation 
of  the UGIB event with the early bleeders presenting in 
the first few months of  starting treatment and the late 
bleeders after at least one year of  therapy. Patients who 
had an event were likely to be hospitalized and required 
blood transfusion.
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